Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland
Open accessThe DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the contemporaneous prevalence of diabetic peripheral neuropathy (DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional association with risk factors and other diabetic complications. RESEARCH DESIGN AND METHODS: We analyzed data from a large representative sample of adults with T1D (N = 5,558). We assessed the presence of symptomatic neuropathy using the dichotomized (≥4) Michigan Neuropathy Screening Instrument Patient Questionnaire score. Logistic regression models were used to investigate associations between DPN and risk factors, as well as with other complications. RESULTS: The burden of DPN is substantial with 13% prevalence overall. Adjusting for attained age, diabetes duration, and sex, the odds of DPN increased mainly with waist-to-hip ratio, lipids, poor glycemic control (odds ratio 1.51 [95% CI 1.21–1.89] for levels of 75 vs. 53 mmol/mol), ever versus never smoking (1.67 [1.37–2.03]), and worse renal function (1.96 [1.03–3.74] for estimated glomerular filtration rate levels <30 vs. ≥90 mL/min/1.73 m2). The odds significantly decreased with higher HDL cholesterol (0.77 [0.66–0.89] per mmol/L). Living in more deprived areas was associated with DPN (2.17 [1.78–2.65]) for more versus less deprived areas adjusted for other risk factors. Finally, individuals with prevalent DPN were much more likely than others to have other diabetes complications. CONCLUSIONS: Diabetic neuropathy remains substantial, particularly affecting those in the most socioeconomically deprived groups. Those with clinically manifest neuropathy also have a higher burden of other complications and elevated levels of modifiable risk factors. These data suggest that there is considerable scope to reduce neuropathy rates and narrow the socioeconomic differential by better risk factor control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“73m2) were computed using the CKD Epidemiology Collaboration formula eGFR (24).”
MethodMultimodel Inference: Understanding AIC and BIC in Model Selection
Burnham, K. P., & Anderson, D. R. (2004) · Sociological Methods & Research · doi:10.1177/0049124104268644 · Cited by 11,648
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211 · cited 1×
“Drug treatment of DPN mainly comprises symptom control using anticonvulsants and antidepressants (7,12, 13), with duloxetine and pregabalin being among the first-line therapies indicated in the major guidelines (14).”
BackgroundTesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 4×
“The data reinforce previous findings (26) and give support to the idea of a holistic, comprehensive approach to diabetes management.”
BackgroundResultInfluential
Research works printed but not linked: 1
- Scottish Intercollegiate Guidelines Network, 2010, Management of Diabetes: A National Clinical Guideline
Cited by
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00188-0 · Cited by 387
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“For example, when using questionnaires like MNSIQ, the prevalence of DN in T1DM patients is estimated at 11 – 13%; 29,30 however, when structured clinical examinations and vibration perception thresholds are used, the prevalence increases to 28%.”
Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., Benham, J. L., Bodhini, D., Clark, A. L., Colclough, K., Corcoy, R., Cromer, S. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02502-5 · Cited by 217
Progress in the treatment of diabetic peripheral neuropathy
Yang, K., Wang, Y., Li, Y.-W., Chen, Y.-G., Xing, N., Lin, H.-B., Zhou, P., & Yu, X.-P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112717 · Cited by 161
The global and regional burden of diabetic peripheral neuropathy
Savelieff, M. G., Elafros, M. A., Viswanathan, V., Jensen, T. S., Bennett, D., & Feldman, E. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01041-y · Cited by 195
“In a study in patients with T1D in Scotland, those with more severe socioeconomic deprivation were more likely to have DPN, following adjustment for other neuropathy risk factors, including age, diabetes duration, obesity, dyslipidaemia and comorbid microvascular disease 156 .”
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 103
Yapislar, H., & Gurler, E. B. (2024) · Biomedicines · doi:10.3390/biomedicines12091958 · Cited by 64
“Individuals with DPN typically experience pain in their limbs, particularly toward the extremities, and often describe a sensation similar to wearing gloves and socks [90].”
BackgroundThe conundrum of diabetic neuropathies—Past, present, and future
Ang, L. P., Mizokami‐Stout, K., Eid, S., Elafros, M. A., Callaghan, B. C., Feldman, E. L., & Pop‐Busui, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108334 · Cited by 66
Pop‐Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z., & DCCT/EDIC Research Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13635 · Cited by 52
Wang, R., Li, B., Dong, M., Zhu, H., Jin, P., & Zou, Y. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf020 · Cited by 55
“Additionally, the accumulation of polyols and the formation of AGEs promoted by high blood sugar levels can lead to metabolic and microvascular changes that impair nerve function [69, 70].”
Psychosocial Care for People With Diabetic Neuropathy: Time for Action
Pouwer, F., Mizokami‐Stout, K., Reeves, N. D., Pop‐Busui, R., Tesfaye, S. H., Boulton, A. J. M., & Vileikytė, L. (2023) · Diabetes Care · doi:10.2337/dci23-0033 · Cited by 47
Innovative therapies for diabetic foot ulcers: Application and prospects of smart dressings
Zhao, X. Q., Zhang, Y., Huang, Z., Wu, X., & Lin, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118498 · Cited by 40
Obesity-related neuropathy: the new epidemic
Elafros, M. A., Reynolds, E. L., & Callaghan, B. C. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001292 · Cited by 27
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes
Braffett, B. H., ghormli, L. K. E., Albers, J. W., Feldman, E. L., Herman, W. H., Gubitosi‐Klug, R., Martin, C. L., Orchard, T. J., White, N. H., Lachin, J. M., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1749 · Cited by 23
Cuyubamba, O., Braga, C., Swift, D. D., Stickney, J. T., & Viel, C. (2025) · Cells · doi:10.3390/cells14070477 · Cited by 20
“While the risk factor with the strongest association for developing DPN is poor glycemic control [20–22], other independent risk factors like obesity, an increased waist-to-hip ratio, hypertension, dyslipidemia, hypertriglyceridemia and smoking are well-described [20,21,23–26].”
Purohit, S. B., Tran, P. M. H., Tran, L. K. H., Satter, K. B., He, M., Zhi, W., Bai, S., Hopkins, D., Gardiner, M., Wakade, C. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654233 · Cited by 20
“It was 13% in a Scottish registry population study (12), 11% in the 25,000‐person T1D Exchange Clinic Network in the U.”
BackgroundThe Epidemiology of Diabetic Neuropathy
Hansen, C. S., Määttä, L. L., Andersen, S. T., & Charles, M. H. (2023) · Contemporary Diabetes · doi:10.1007/978-3-031-15613-7_2 · Cited by 17
Chen, M., Pu, L., Gan, Y., Wang, X., Kong, L., Guo, M., Yang, H., Li, Z., & Xiong, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-56777-w · Cited by 21
Guo, Y., Zeng, J., Zhuang, Y., Jiang, C., & Xie, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-65096-z · Cited by 16
Mittal, R., McKenna, K., Keith, G., McKenna, E., Lemos, J. R. N., Mittal, J., & Hirani, K. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00270 · Cited by 22
Brock, C., Andersen, H., Alibegovic, A. C., Andersen, S. R. D., Andreasen, L., Charles, M., Christensen, D. H., Drewes, A. M., Gall, M.-A., Gylfadottir, S. S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112010 · Cited by 12
Advances in the pathophysiology and treatment of diabetic peripheral neuropathy
Fridman, V., Elafros, M. A., Eid, S., Reynolds, E. L., McCray, B. A., & Callaghan, B. C. (2026) · BMJ · doi:10.1136/bmj-2024-081217 · Cited by 16
Zhang, L., Sun, X., & Tian, Q. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02241-0 · Cited by 12
Nerve decompression for diabetic peripheral neuropathy with nerve entrapment: a narrative review
Liao, C., & Zhang, W. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241265287 · Cited by 10
“13 Increased glucose metabolism results in overactivation of the hexosamine, 14 polyol, 15 and protein kinase C pathways, 16 as well as excessive generation of advanced glycation end products (AGEs) and/or receptor-associated AGE activation (RAGE).”
Höhn, A., McGurnaghan, S. J., Caparrotta, T. M., Jeyam, A., O’Reilly, J. E., Blackbourn, L. A. K., Hatam, S., Dudel, C., Seaman, R., Mellor, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271110 · Cited by 12
“Socioeconomic differences have also been identified regarding the management of type 1 diabetes, such as glucose control [8, 9] and complications, including the prevalence of diabetic neuropathy [10] and diabetic retinopathy [11].”
BackgroundSelf-citationTian, Z., Fan, Y., Sun, X., Wang, D., Guan, Y., Zhang, Y., Zhang, Z., Guo, J., Bu, H., Wu, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17339 · Cited by 9
Walker, B. B., Brinkmann, S. T., Große, T., Kremer, D., Schuurman, N., Hystad, P., Rangarajan, S., Teo, K. K., Yusuf, S., & Lear, S. A. (2022) · Journal of Urban Health · doi:10.1007/s11524-022-00630-w · Cited by 10
“Our modelling results largely correspond with previous studies, in that low household income [4] and tobacco use [2, 35] were significant risk factors.”
BackgroundResultInfluentialAzarboo, A., Fallahtafti, P., Javidan, A., Zareshahi, N., Giglou, H. S., Moayyed, S., Raeini, A. G., & Hemmatabadi, M. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103223 · Cited by 8
Sebastián‐Valles, F., de Arenas‐Arroyo, S. N., Simó‐Servat, O., Simó, R., Painter, H., Martín, J. A. A., Navas-Moreno, V., Marazuela, M., Martínez‐Vizcaíno, V., & Alfonso, J. M. (2025) · BMC Medicine · doi:10.1186/s12916-025-04559-0 · Cited by 7
Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study
Pasha, R., Kamath, A., Linn, Z., Kalteniece, A., Bashir, B., Schofield, J. D., Malik, R. A., Azmi, S., Ferdousi, M., & Soran, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16617 · Cited by 7
“33 However, Svendsen et al. reported no significant impact on nerve conduction or intraepidermal nerve fibre density among statin users, 18,34 and other studies report no association between statins and peripheral neuropathy 35 or idiopathic small fibre neuropathy.”
Mizokami‐Stout, K., Li, Z., Foster, N. C., Ang, L. P., & Pop‐Busui, R. (2020) · Diabetes Care · doi:10.2337/dci20-0028 · Cited by 7
The association between smoking and diabetic neuropathy: a systematic review and meta-analysis
Bader, S., Hasan, S., Magliano, D. J., Islam, R. M., Palawaththa, S., Romero, L., & Karim, M. N. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02995-w · Cited by 6
Racial and Ethnic Differences in Peripheral Neuropathy Risk Factors Among United States Adults
Reynolds, E. L., Russman, D., Elafros, M. A., Feldman, E. L., & Callaghan, B. C. (2025) · Neurology · doi:10.1212/wnl.0000000000213851 · Cited by 8
Rethinking Neuropathy in Type 1 Diabetes: Had We Lost Sight of What Matters Most?
Perkins, B. A. (2020) · Diabetes Care · doi:10.2337/dci19-0076 · Cited by 6
“In this issue of Diabetes Care, two articles report on the prevalence and factors associated with diabetic neuropathy using this simple measurement approach.”
BackgroundResultInfluentialMa, S., Huang, H., Xue, F., Wang, Q., Yu, S., Hou, Q., Li, M., & Wang, H. (2024) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2024.102376 · Cited by 5
Zhao, Q., Wang, J., Liu, F., Jiang, H., & Ma, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1496635 · Cited by 5
Anandan, C., Horak, H. A., Patel, K., & AANEM (2025) · Muscle & Nerve · doi:10.1002/mus.70015 · Cited by 5
“Other studies have shown the prevalence of DPN in patients with T1Ds to range from 11% to 13% [8, 9].”
Sima, C., Wang, Z., Wang, S., Wang, H., Sun, Z., Wang, H., Liang, D., Li, J., & Zhang, Z. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1708426 · Cited by 5
Yu, Z., Yang, J., Jiang, Y., Wei, M., Lyu, Y., Yang, D., Shen, S., Han, Y., & Li, M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01376-x · Cited by 4
Klowak, M., Lau, R., Mohammed, M., Birago, A., Samson, B., Ahmed, L., Renee, C., Meconnen, M., Bado, E., Reid-John, A., et al. (2025) · NeuroSci · doi:10.3390/neurosci6030074 · Cited by 3
Pop‐Busui, R., Petersen, E., Levy, B. L., Tesfaye, S. H., Armstrong, D. G., Grunberger, G., Boulton, A. J. M., Bharara, M., Edgar, D. R., Province‐Azalde, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101647 · Cited by 4
Inceu, G., Rusu, A., Gavan, N. A., & Bala, C. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226858 · Cited by 2
“The importance of psychosocial and economic factors in diabetic neuropathy has recently gained more attention, and socioeconomic status was found to be a risk factor for diabetic neuropathy in different populations [3,4].”
The Challenges and Obstacles in Diagnosing Neuropathy in Patients With Diabetes
Pinzon, M. C. A. N. L., Letsoin, R. T. P., & Sugianto, S. (2024) · Saintika Medika · doi:10.22219/sm.vol20.smumm2.36581 · Cited by 2
Aguiar, C. H., Pedrosa, H. C., Tannus, L. R. M., Ferreira, L. L., Da, S., Pôrto, L. C., Negrato, C. A., & Gomes, M. B. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70049 · Cited by 2
“However, it is important to highlight that some SDOH are not included in the official socioeconomic assessment of the Brazilian population, such as neighborhood environment, food insecurity, access to health care, and stress, while some of these factors have been linked to DPN [9].”
InfluentialDiabetic Polyneuropathy: from Pathogenesis to Pathogenetic Therapy
Tanashyan, M. М., State, F. S. A. E. I. O. H. E. ‘. M. S. F. M., Антонова, К. В., Спрышков, Н. Е., Панина, А. А., Лагода, О. В., & Shchukina, E. P. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-8-54-62 · Cited by 3
Yang, J., Kong, L., Zhang, W., Song, X., Han, J., Sun, W., & Zhou, X. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01104-0 · Cited by 2
Pappa, A., Häusler, M., Tittel, S. R., Boettcher, C., Hilgard, D., Knauer-Fischer, S., Pavel, M., Woelfle, J., & Holl, R. W. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0074 · Cited by 2
Zhuang, R., Xiong, Z., Yan, S., Zhang, H., Dong, Q., Liu, W., Miao, J., Zhuo, Y., Fan, X., Zhang, W., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079354 · Cited by 1
Lin, K., Wang, X., Gu, T., Feng, K., Wang, Z., & Liu, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s485853 · Cited by 1
Zhao, F., Lv, J., Yang, M., Zhang, F., Zhang, C., Wang, F., & Wang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108807 · Cited by 1
Integrating gut microbiota into multidisciplinary perspectives on diabetic neuropathy
Horiachok, M., Potapova, K., Ivanykovych, T., Yerokhovych, V., Ilkiv, Y., & Sokolova, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710868 · Cited by 1
Tian, Z., Fan, Y., Sun, X., Wang, D., Guan, Y., Zhang, Y., Zhang, Z., Guo, J., Bu, H., Wu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2096555/v1
Advances in the Treatment of Diabetic Peripheral Neuropathy
郭, 羽. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361262
Causal relationship between dyslipidemia and diabetic neuropathy: a mendelian randomization study
Li, C., Yu, F., Feng, L., & Li, M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01448-y
“HDL levels are usually low in DM patients, and the function of HDL is impaired (Jeyam et al. 2020 ).”
Zhao, Y., Wang, L., & Feng, D. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70199
“Diabetes is a metabolic disorder characterized by hyperglycemia, featuring extremely high global morbidity and mortality, and can trigger various complications 1 – 3 .”
Hu, X., Liu, W. T., Fang, Y., Zhu, Y., Zhang, M., Gong, S., Wang, X., Lin, C., Liu, G., Yang, X., et al. (2026) · Health Data Science · doi:10.34133/hds.0298
“These include diabetes duration, poor glycemic control, smoking, and metabolic disorders such as hypertension, hyperlipidemia, and obesity [ 33 – 39 ].”
Klowak, M., Bado, E., Reid-John, A., Dawood, R., Madakadze, C., & Boggild, A. K. (2026) · Brain Sciences · doi:10.3390/brainsci16060551
“…for both the effect of alcohol consumption and dependence on the prevalence of neuropathy/NP indicate a protective effect, whereby alcohol use is associated with 50%, and 40% lower prevalence of neuropathy compared to non-use, respectively [39,42,43,46,48,51,57–59, 67, 70, 73, 80, 84, 85].”
Jin, A. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.10.278.1
Harper, C. A. A., Marsh, J. S., Fernandes, M., Sagar, R. C., Synowsky, S. A., Ahmed, H., Shirran, S. L., Naseem, K. M., Ajjan, R., & Stewart, A. J. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2873-8027
“…knowledge gap is critical for understanding the interplay between metabolic and vascular risk factors in T1D To investigate the molecular drivers of thrombotic risk in T1D, we adopted an integrative approach combining functional clotting and brinolysis assays with plasma proteomics This analysis ,”
Metadata
- Authors
- Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M.
- Affiliations
- Institute of Genetics and Cancer (GB)
- NHS Lothian (GB)
- Dumfries and Galloway Royal Infirmary (GB)
- University Hospital Ayr (GB)
- University of Edinburgh (GB)
- National Health Service (GB)
- Corresponding author
- Jeyam, Anita
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-23
- Volume
- 43
- Issue
- 4
- Pages
- 734-742
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3002419256
- Semantic Scholar
- 797905057922d7edb07aa82ecfc9c634ef3b3724
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 16 · 2023: 6 · 2022: 8 · 2021: 3 · 2020: 2
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Chief Scientist Office (ETM/47)
- Diabetes UK (10/0004010)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- diabetic peripheral neuropathy, type 1 diabetes, socioeconomic deprivation, prevalence, risk factors, glycemic control, renal function, smoking, waist-to-hip ratio, lipids, HDL cholesterol, diabetes complications, Michigan Neuropathy Screening Instrument, Scotland
- MeSH terms
- Adolescent, Adult, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Male, Middle Aged, Risk Factors, Scotland, Socioeconomic Factors, Prevalence, Vulnerable Populations, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.